ArticleBiophysics reports2025
Exploring diet-microbiota interactions and therapeutic nutrition management in inflammatory bowel disease.
Article in Biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of the substrate profile of microbial-host-isozyme reveals the role of BvDPP4 in inflammatory bowel disease.Science China. Life sciences · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal bowel disease (IBD) is a chronic, early-onset, recurrent gastrointestinal immune-related disease that has become globalized. Although the combination of genetic, environmental, and immunological factors leads to intestinal inflammation and barrier damage, the etiology of IBD is not clearly defined. In recent years, diet-microbiota interactions have been widely studied for their potential in pathogenesis and treatment for IBD. Meanwhile, the significant efficacy of exclusive enteral nutrition (EEN) has been observed in clinical practice with modulation in gut microbiota, but the specific mechanisms and optimization measures remain challenging. Therefore, we first describe the development of existing microbial research techniques and the perspectives that can be broadened. We then synthesize findings on how dietary components impact IBD progression and treatment through microbiota. Finally, based on correlating clinical and basic experiments, we summarize the current status and potential mechanisms of EEN for treating IBD, especially the contradictory points encountered in its application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.